Inhibikase Therapeutics (IKT) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 27, 2025, with shareholders able to attend, vote, and ask questions online.

• Shareholders of record as of May 1, 2025, are eligible to vote on the proposals.

• Proxy materials and the 2024 Annual Report are available online, with options for electronic or paper delivery.

• The Board recommends voting in favor of all proposals presented.

Voting matters and shareholder proposals

• Election of two Class II directors, Amit Munshi and David Canner, Ph.D., to serve until 2028.

• Ratification of CohnReznick LLP as independent auditor for fiscal year ending December 31, 2025.

• Approval of an amendment to the 2020 Equity Incentive Plan to add an automatic “evergreen” provision and extend the plan to 2035.

• Shareholders may submit additional proposals or director nominations for future meetings, following specific procedures.

Board of directors and corporate governance

• The Board consists of eight members divided into three staggered classes, with annual elections for one class.

• Majority of directors are independent under Nasdaq and SEC rules; only the CEO is not independent.

• Board committees include audit, compensation, and corporate governance/nominating, each with defined charters and independent members.

• The Chairperson and CEO roles are separated to reinforce board independence.

• Directors are encouraged to attend meetings, and all attended at least 75% of meetings in 2024.